Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun:7:1084-1092.
doi: 10.1200/GO.21.00087.

Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19

Guilherme Nader Marta  1   2 , Renata Colombo Bonadio  1   3 , Odeli Nicole Encinas Sejas  4 , Gabriel Watarai  1 , Maria Cecilia Mathias Machado  1 , Lorena Teixeira Frasson  1 , Camila Motta Venchiarutti Moniz  1   3 , Raquel Keiko de Luca Ito  4 , Driele Peixoto  4 , Camilla Oliveira Hoff  5 , Veruska Menegatti Anastacio  6 , Ulysses Ribeiro Jr  7 , Juliana Pereira  8 , Vanderson Rocha  8 , Edson Abdala  4 , Maria Del Pilar Estevez-Diz  1 , Paulo M Hoff  1   3
Affiliations

Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19

Guilherme Nader Marta et al. JCO Glob Oncol. 2021 Jun.

Abstract

Purpose: Patients with cancer are at increased risk for unfavorable outcomes from COVID-19. Knowledge about the outcome determinants of severe acute respiratory syndrome coronavirus 2 infection in this population is essential for risk stratification and definition of appropriate management. Our objective was to evaluate prognostic factors for all-cause mortality in patients diagnosed with both cancer and COVID-19.

Methods: All consecutive patients with cancer hospitalized at our institution with COVID-19 were included. Electronic medical records were reviewed for clinical and laboratory characteristics potentially associated with outcomes.

Results: Five hundred seventy-six consecutive patients with cancer and COVID-19 were included in the present study. An overall in-hospital mortality rate of 49.3% was demonstrated. Clinical factors associated with increased risk of death because of COVID-19 were age over 65 years, Eastern Cooperative Oncology Group performance status > 0 zero, best supportive care, primary lung cancer, and the presence of lung metastases. Laboratory findings associated with a higher risk of unfavorable outcomes were neutrophilia, lymphopenia, and elevated levels of D-dimer, creatinine, C-reactive protein, or AST.

Conclusion: A high mortality rate in patients with cancer who were diagnosed with COVID-19 was demonstrated in the present study, emphasizing the need for close surveillance in this group of patients, especially in those with unfavorable prognostic characteristics.

PubMed Disclaimer

Conflict of interest statement

Guilherme Nader MartaTravel, Accommodations, Expenses: Bayer Schering Pharma, Roche Renata Colombo BonadioResearch Funding: Novartis, AstraZenecaExpert Testimony: AcheTravel, Accommodations, Expenses: Roche, AstraZeneca Driele Peixoto BittencourtHonoraria: Novo Nordisk, EMS, GE Healthcare, NovartisConsulting or Advisory Role: Bayer Camilla Oliveira HoffLeadership: Rede D'OrStock and Other Ownership Interests: OncostarHonoraria: Bayer, Exelixis, Lilly, United MedicalConsulting or Advisory Role: Bayer, Exelixis, United Medical, LillyResearch Funding: Exelixis, Lilly Juliana PereiraConsulting or Advisory Role: AstraZeneca Vanderson RochaHonoraria: Takeda, Novartis, RocheConsulting or Advisory Role: Takeda, Agios, Zodiac Pharma, Novartis, AbbVieSpeakers' Bureau: Bristol Myers Squibb, Takeda, Amgen, Agios, Pfizer, Janssen Paulo M. HoffLeadership: Oncologia D'OrStock and Other Ownership Interests: OncoStar Oncology ClinicsHonoraria: Bayer Health, United MedicalConsulting or Advisory Role: United Health Group, Bayer, Lilly, ExelixisResearch Funding: Bayer, MSD Oncology, Novartis, Exelixis, Roche/Genentech, AstraZeneca/MedImmune, LillyNo other potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
Supportive therapy received by patients with cancer hospitalized in an intensive care unit during COVID-19 infection (n = 225).
FIG 2
FIG 2
Graphical representation of mortality rates of patients with cancer and COVID-19 infection. BSC, best supportive care; NED, no evidence of disease.
See this image and copyright information in PMC

References

    1. Zhu N Zhang D Wang W, et al. : A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727-733, 2020 - PMC - PubMed
    1. Zhou F Yu T Du R, et al. : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395:1054-1062, 2020 - PMC - PubMed
    1. Li J-Y Duan X-F Wang L-P, et al. : Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res 2014:286170, 2014 - PMC - PubMed
    1. Landman A, Feetham L, Stuckey D: Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 21:335-337, 2020 - PMC - PubMed
    1. Schrag D, Hershman DL, Basch E: Oncology practice during the COVID-19 pandemic. JAMA 323:2005-2006, 2020 - PubMed